This is a contrast between Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Evogene Ltd. (NASDAQ:EVGN) based on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals Incorporated	251.45M	10.39	143.32M	5.64	21.77
Evogene Ltd.	N/A	0.00	N/A	-0.82	0.00

Table 1 highlights Ligand Pharmaceuticals Incorporated and Evogene Ltd.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both businesses.

	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals Incorporated	57.00%	21.6%	8.9%
Evogene Ltd.	0.00%	0%	0%

Analyst Ratings

Ligand Pharmaceuticals Incorporated and Evogene Ltd. Ratings and Recommendations are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Ligand Pharmaceuticals Incorporated	0	0	2	3.00
Evogene Ltd.	0	0	0	0.00

Ligand Pharmaceuticals Incorporated has an average price target of $222, and a 73.65% upside potential.

Insider & Institutional Ownership

Insiders held 2.1% of Ligand Pharmaceuticals Incorporated shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Ligand Pharmaceuticals Incorporated	-0.66%	3.89%	-24.58%	-52.2%	-20.61%	-9.59%
Evogene Ltd.	1.32%	0%	-13.13%	-21.45%	-28.84%	14.65%

For the past year Ligand Pharmaceuticals Incorporated had bearish trend while Evogene Ltd. had bullish trend.

Summary

Ligand Pharmaceuticals Incorporated beats Evogene Ltd. on 10 of the 11 factors.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants, which include microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 24 products in various stages of development. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.